Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PYXS | 8-K | mixed | 6/10 | Pyxis Oncology entered into a securities purchase agreement for a $50 million private placement (plus up to $64 million | Jul 2, 2026 |
| BEAM | CLUSTER | mixed | 5/10 | A cluster of insider selling at Beam Therapeutics materialized over June 26-30, 2026, totaling $8.95M. The CEO exercised | Jul 2, 2026 |
| ARTL | DEFA14A | bearish | 6/10 | Artelo Biosciences filed supplemental proxy materials adding Proposal 3 to its 2026 annual meeting agenda: stockholder a | Jul 2, 2026 |
| INM | S-4 | bearish | 7/10 | InMed Pharmaceuticals filed an S-4 registration statement for its merger with Mentari Therapeutics. The deal is structur | Jul 2, 2026 |
| XENE | PRESS-RELEASE | neutral | 1/10 | Xenon Pharmaceuticals granted 20,200 stock options and 11,850 RSUs to four new non-officer employees as inducement equit | Jul 2, 2026 |
| INO | S-3 | bearish | 6/10 | Inovio Pharmaceuticals (INO) filed a universal shelf registration statement on Form S-3 on July 2, 2026, to raise up to | Jul 2, 2026 |
| ABVC | 8-K | bearish | 6/10 | ABVC BioPharma dismissed auditor Simon & Edward, LLP (S&E) and engaged Kreit & Chiu CPA LLP (KC) as its new independent | Jul 2, 2026 |
| QURE | 144 | neutral | 2/10 | CEO Matthew Kapusta filed a Form 144 to sell 21,082 ordinary shares valued at ~$952K. The notice indicates the sale is p | Jul 2, 2026 |
| LIXT | 8-K | neutral | 5/10 | { "summary": "LIXTE Biotechnology completed its transformative reverse merger with NOMAD Transportable Power Systems o | Jul 2, 2026 |
| INBP | 8-K | neutral | 3/10 | Integrated BioPharma entered into an amendment with PNC Bank that extends its $4M revolving credit facility maturity by | Jul 2, 2026 |
| UNCY | 8-K | neutral | 3/10 | Unicycive Therapeutics disclosed a preliminary cash balance of approximately $61.4 million as of June 30, 2026, via an 8 | Jul 2, 2026 |
| MGNX | PRESS-RELEASE | bullish | 6/10 | MacroGenics completed the sale of its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million, transitio | Jul 2, 2026 |
| RNXT | 8-K | bearish | 6/10 | RenovoRx received a second 180-day extension from Nasdaq until December 28, 2026 to regain compliance with the $1.00 min | Jul 2, 2026 |
| TRIB | 6-K | neutral | 4/10 | Trinity Biotech announced clinical data from its CGM+ wearable biosensor platform, demonstrating ability to distinguish | Jul 2, 2026 |
| ELTX | 424B5 | bearish | 6/10 | Elicio Therapeutics is raising approximately $13.6 million in net proceeds through a registered direct offering of 4,380 | Jul 2, 2026 |
| TENX | 8-K | neutral | 6/10 | Tenax Therapeutics announced that results from its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) in PH-HFpEF will b | Jul 2, 2026 |
| RVMD | PRESS-RELEASE | bullish | 7/10 | Revolution Medicines reported positive Phase 1/2 data for zoldonrasib in RAS G12D metastatic pancreatic cancer at ESMO G | Jul 2, 2026 |
| VRXA | PRESS-RELEASE | neutral | 3/10 | VERAXA Biotech announced the initiation of cell line development for its lead BiTAC-TCE program with ATUM, a critical bu | Jul 2, 2026 |
| ARCT | 8-K | bullish | 6/10 | Arcturus Therapeutics entered into a strategic collaboration with Thermo Fisher Scientific to provide CRO and CDMO servi | Jul 2, 2026 |
| VXRT | 8-K | neutral | 4/10 | Vaxart entered a cooperation agreement with a stockholder group (holding ~0.6% of shares) to end a proxy contest ahead o | Jul 2, 2026 |
| ELTX | 8-K | bearish | 6/10 | Elicio Therapeutics announced a $15 million registered direct offering, issuing 4,380,313 shares at $3.43 per share to i | Jul 2, 2026 |
| TENX | PRESS-RELEASE | neutral | 7/10 | Tenax Therapeutics announced that Phase 3 LEVEL trial results for TNX-103 (oral levosimendan) in PH-HFpEF will be presen | Jul 2, 2026 |
| CUE | EFFECT | bearish | 6/10 | Cue Biopharma's S-3 shelf registration (File No. 333-296896) was declared effective by the SEC on July 1, 2026, enabling | Jul 2, 2026 |
| MOLN | 6-K | neutral | 5/10 | Molecular Partners announced the first patients have been dosed in a Phase 1/2a trial of MP0712, a DLL3-targeting Radio- | Jul 2, 2026 |
| MAZE | CLUSTER | neutral | 3/10 | A cluster of insider sales at Maze Therapeutics involving the CEO ($622K) and the head of CSBO ($210K) for a total of $8 | Jul 2, 2026 |
| CADL | CLUSTER | neutral | 2/10 | Two C-suite insiders at Candid Therapeutics sold a combined ~$306K in open-market transactions on June 29, representing | Jul 2, 2026 |
| RAPP | CLUSTER | neutral | 3/10 | CEO Abraham Ceesay and COO Cheryl Gault sold a combined ~$368K worth of RAPP shares in open-market transactions on June | Jul 2, 2026 |
| BEAM | CLUSTER | bearish | 4/10 | CEO John M. Evans exercised options and sold shares worth ~$1.26M, while 10% owner FMR LLC sold 251,488 shares (~$8.87M) | Jul 2, 2026 |
| ZLAB | CLUSTER | neutral | 3/10 | Four Zai Lab insiders, including the CEO, CFO, and Chief Legal Officer, sold a total of ~$667K in open-market sales over | Jul 2, 2026 |
| ROIV | CLUSTER | bearish | 5/10 | Six Roivant insiders, including the President & CIO and the President & Immunovant CEO, sold a total of ~$43.3M in open- | Jul 2, 2026 |